Camie Chan

Camie Chan has a diverse work experience spanning over two decades. Camie currently serves as the Chief Executive Officer of Xellera Therapeutics since August 2022. Prior to this, they held the position of Chief Operating Officer at Xellera Therapeutics from June 2019 to December 2022. Camie also held a similar role as the Chief Operating Officer at Medera Biopharmaceutical starting from November 2020.

Camie has experience in the healthcare and biotechnology industry, as evidenced by their role as the Interim Chief Financial Officer at Novoheart in both 2019 and 2020. Before entering the corporate world, they worked as an Assistant Professor at the Department of Anatomy and Medicine in the LKS Faculty of Medicine at The University of Hong Kong from 2010 to 2016. Prior to this, they held the position of Assistant Professor at the Department of Cell Biology & Human Anatomy at the University of California, Davis from 2006 to 2010.

Camie's earlier roles include serving as an Assistant Investigator at the Institute of Pediatric Regenerative Medicine at Shriners Hospitals for Children from 2006 to 2010, and as a Postdoctoral Fellow at Johns Hopkins Hospital from 2002 to 2006.

Overall, Camie Chan's work experience showcases their expertise in executive leadership, operations management, and their contributions to the fields of anatomy, medicine, and regenerative medicine.

Camie Chan has an extensive education history. Camie obtained a Bachelor of Science (BSc Hons) degree in Biochemistry and Biotechnology from the University of Waterloo in 1994. Following that, they pursued further education and earned a Master of Science (MS) degree from the University of Toronto in 1996. Building on their expertise, they continued their academic journey at the University of Toronto and completed a Doctor of Philosophy (PhD) degree, specializing in an unspecified field of study. In addition to their academic qualifications, Camie Chan also has a certification in the "ADVANCE 5-Day Workshop for ATMP Developers," which they obtained from the ADVANCE ATMP Training Programme, although the specific month and year of its completion are not provided.